EMA OKs Sublingual Formulation for Opioid Dependence 🔗 Access full article via Medscape NeurologyThe new buprenorphine formulation is used as a substitution treatment in adults and adolescents 15 years or older who agree to be treated for addiction. Medscape Medical News Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
